CALDERWOOD & HARKNESS LLP 200 Park Avenue, 42nd Floor New York, New York 10166
PRIVILEGED AND CONFIDENTIAL ATTORNEY-CLIENT COMMUNICATION / ATTORNEY WORK PRODUCT
MEMORANDUM
Date: August 25, 2024
To:
Dr. Anand Rajagopal, Chief Executive Officer, Penterra Pharmaceuticals Corp.
Thomas F. Holbrook, General Counsel & Secretary, Penterra Pharmaceuticals Corp.
Natalie Reiner, SVP, Corporate Development, Penterra Pharmaceuticals Corp.
From:
Oliver Mackenzie, Partner
Megan Chu, Associate
Derek Okonkwo, Associate
Re: Material Adverse Effect Analysis — Marlowe Asset Management-2 Phase II Interim Clinical Data for VRD-4187
Matter No.: 1018-00008
CONFIDENTIALITY NOTICE: This memorandum is a privileged and confidential attorney-client communication and attorney work product prepared by Calderwood & Harkness LLP in connection with the proposed acquisition of Veridian Biosciences, Inc. by Penterra Pharmaceuticals Corp. under the Stock Purchase Agreement dated June 10, 2024. This memorandum contains legal analysis and advice protected by the attorney-client privilege and the work product doctrine. It is intended solely for the use of the named recipients and should not be distributed, disclosed, or shared with any other person or entity without the prior written consent of counsel. Any unauthorized distribution may constitute a waiver of privilege.
I. EXECUTIVE SUMMARY
The purpose of this memorandum is to analyze whether the interim clinical data from the Marlowe Asset Management-2 Phase II trial of VRD-4187, as reported by the independent Data Monitoring Committee ("DMC") on August 14, 2024, constitutes a "Material Adverse Effect" as that term is defined in Section 1.1 of the Stock Purchase Agreement dated June 10, 2024 (the "SPA") between Penterra Pharmaceuticals Corp. ("Penterra" or "Buyer") and Veridian Biosciences, Inc. ("Veridian" or the "Company"). This analysis has been prepared at the request of Penterra's management team and General Counsel to assist in evaluating Penterra's rights and obligations under the SPA in light of the recently disclosed clinical data.
Based on the analysis set forth below, it is our view that there are strong arguments that the Marlowe Asset Management-2 interim data has had, or would reasonably be expected to have, a Material Adverse Effect on the business, results of operations, financial condition, or assets of Veridian, taken as a whole. The interim data reveals a severely unfavorable safety profile for VRD-4187, including a statistically significant increase in Grade ≥3 cytokine release syndrome ("CRS") (23.4% in the VRD-4187 treatment arm versus 4.1% in the control arm), seven treatment-related deaths (3.6% versus 0.5%), and a non-statistically significant difference in overall response rate ("ORR") (31.4% versus 28.9%, p = 0.58). Taken together, these data points indicate that VRD-4187, at the tested dose, does not offer a meaningful therapeutic benefit over the standard of care and carries an unacceptably elevated safety risk. For a pre-revenue, clinical-stage company whose entire enterprise value is derived from the probability-adjusted net present value of its pipeline — overwhelmingly concentrated in VRD-4187 — these data represent a fundamental impairment of Veridian's business and financial condition.
We note that this analysis does not address the FDA partial clinical hold imposed on August 22, 2024 on IND 154832 (which occurred after the DMC data readout and after Penterra received formal notification of the interim results). A supplemental analysis incorporating the clinical hold and its implications for the MAE determination will follow separately and is expected to further strengthen Penterra's position.
A critical caveat is warranted. Delaware courts apply a very high bar to Material Adverse Effect determinations. The burden of proof rests entirely on the buyer, and the Delaware Court of Chancery has historically been reluctant to permit buyers to invoke MAE clauses to terminate transactions. indeed, prior to Akorn, Inc. v. Fresenius Kabi AG, C.A. No. 2018-0300-JTL (Del. Ch. Oct. 1, 2018), aff'd, 198 A.3d 724 (Del. 2018), no Delaware court had ever found that an MAE had occurred in a contested proceeding. Accordingly, while we believe the factual record here is exceptionally strong — and materially distinguishable from prior cases in which MAE claims failed — success is not guaranteed. The strength of Penterra's position is significantly enhanced, however, by the fact that VRD-4187 is Veridian's lead pipeline asset and the primary driver of the $900 million purchase price negotiated by the parties. As discussed more fully below, we estimate the probability of Penterra prevailing on the MAE claim, if litigated, at approximately 55–70%.
The remainder of this memorandum is organized as follows: Part II provides relevant background on the transaction, VRD-4187, and the Marlowe Asset Management-2 trial. Part III analyzes the contractual framework governing the MAE determination under the SPA. Part IV surveys the Delaware law framework for MAE determinations. Part V applies the legal framework to the specific facts. Part VI addresses Veridian's anticipated counterarguments. Part VII compares the facts to key Delaware precedents. Part VIII provides an overall assessment of the strength of Penterra's position. Part IX sets forth preliminary recommendations. Part X identifies next steps.
II. BACKGROUND
A. The Transaction
On June 10, 2024, Penterra Pharmaceuticals Corp. ("Penterra" or the "Buyer"), a publicly traded pharmaceutical company listed on the NASDAQ Global Select Market (ticker: PTRA), entered into that certain Stock Purchase Agreement (the "SPA") to acquire 100% of the outstanding capital stock of Veridian Biosciences, Inc. ("Veridian" or the "Company") for an aggregate consideration of $900,000,000 in cash, subject to customary purchase price adjustments for net working capital, cash, indebtedness, and transaction expenses (collectively, the "Transactions"). The SPA was executed by Penterra, the Company, and David Ng, in his capacity as the Stockholder Representative, on behalf of the selling stockholders of Veridian.
Veridian is a clinical-stage biotechnology company organized and existing under the laws of the State of Delaware, with its principal offices located at 550 Gateway Drive, Cambridge, Massachusetts 02142. The Company is focused on the discovery and development of immuno-oncology therapeutics leveraging its proprietary bispecific T-cell engager platform, known as "VeriTCE." Veridian was co-founded in 2016 by Dr. Julian Marek, who serves as the Company's Chief Executive Officer (holding approximately 8.4% of Veridian's outstanding equity), and Dr. Priya Chandrasekaran, who serves as the Company's Chief Scientific Officer (holding approximately 6.2% of Veridian's outstanding equity).
Veridian is a privately held company with no product revenue. For the fiscal year ended December 31, 2023, Veridian reported total revenue of $0, reflecting its pre-commercial status, and reported a net loss of approximately $87.3 million, driven primarily by research and development expenditures and general and administrative expenses. The Company is entirely pre-commercial and has no marketed products, no filed New Drug Applications ("NDAs"), and no pending marketing authorizations in any jurisdiction.
Since its founding, Veridian has raised approximately $420 million in aggregate venture capital financing through Series A, Series B, Series C, and Series D preferred stock rounds. As of March 31, 2024, the Company reported cash and cash equivalents of approximately $112.4 million, representing its most recently reported balance sheet position available at the time of signing. At the time of signing, the Company had approximately 148 full-time employees.
The principal strategic rationale for Penterra's acquisition of Veridian was to bolster Penterra's immuno-oncology pipeline following the Phase III futility analysis of Penterra's internal candidate PPC-0921 in November 2023, which resulted in the discontinuation of that program and a significant gap in Penterra's late-stage oncology pipeline. VRD-4187, Veridian's lead candidate, was the centerpiece of Penterra's deal thesis and the primary driver of the $900 million purchase price. Penterra's Board of Directors approved the Transactions based on the strategic importance of VRD-4187 and its potential to address the unmet medical need in small cell lung cancer ("SCLC") and related DLL3-expressing malignancies.
Veridian's major institutional stockholders include Crestline Ventures, LP (approximately 28.3% of outstanding equity), Boreal Health Partners Fund III, LP (approximately 19.7% of outstanding equity), and Apex Growth Equity Fund II, LP (approximately 14.1% of outstanding equity). David Ng, Managing Partner of Crestline Ventures, LP, serves as the Stockholder Representative under the SPA, authorized to act on behalf of the selling stockholders with respect to post-closing matters, indemnification claims, purchase price adjustments, and related matters.
Veridian's legal counsel in connection with the Transactions is Zalcourt Archer & Cole LLP, with Rebecca Whitmore serving as the lead transaction partner. Penterra engaged Garrison Zanthor & Co. as its financial advisor, with Kevin Driscoll, Managing Director, leading the advisory engagement. Garrison Zanthor & Co. delivered a fairness opinion to Penterra's Board of Directors on June 9, 2024, opining that the $900 million purchase price was fair, from a financial point of view, to Penterra. Penterra also engaged Broadleaf Scientific Consulting LLC ("Broadleaf"), a specialized life sciences consulting firm, to conduct clinical, regulatory, and scientific due diligence on Veridian's pipeline, with Dr. Raymond Kapoor, Managing Director, leading the engagement. Broadleaf's pre-signing due diligence report, delivered on May 28, 2024, identified VRD-4187 as a promising but high-risk candidate and noted the pending interim analysis of the Marlowe Asset Management-2 trial as a key risk factor.
B. VRD-4187 and the Marlowe Asset Management-2 Trial
VRD-4187 is a bispecific T-cell engager antibody designed to redirect cytotoxic T-cells to tumor cells expressing delta-like ligand 3 ("DLL3"), a cell surface protein that is overexpressed in neuroendocrine tumors, including SCLC. VRD-4187 was developed using Veridian's proprietary VeriTCE platform, which enables the engineering of bispecific antibody constructs with enhanced half-life and optimized T-cell engagement properties. The drug candidate has been in clinical development since 2021, when Veridian submitted its Investigational New Drug ("IND") application to the U.S. Food and Drug Administration ("FDA").
VRD-4187 is Veridian's lead clinical candidate and the most advanced asset in the Company's pipeline. It is the primary asset underpinning the $900 million valuation agreed upon by the parties. During Penterra's due diligence process, Broadleaf Scientific Consulting's analysis attributed the substantial majority of Veridian's risk-adjusted enterprise value to VRD-4187, with the Company's two additional earlier-stage immuno-oncology candidates — VRD-5520 (a DLL3×CD3 bispecific targeting neuroendocrine prostate cancer, currently in pre-IND development) and VRD-6003 (a CLDN6×CD3 bispecific targeting ovarian cancer, currently in Phase I dose escalation with fewer than 20 patients enrolled) — contributing only a modest incremental value to the overall transaction valuation. Garrison Zanthor & Co.'s fairness analysis similarly attributed the vast majority of Veridian's value to VRD-4187's projected commercial potential.
The Marlowe Asset Management-2 trial (registered on ClinicalTrials.gov under Identifier NCT05837291) is a randomized, open-label Phase II clinical trial evaluating VRD-4187 as a monotherapy in patients with relapsed or refractory SCLC who have progressed on or after platinum-based chemotherapy. The trial was designed as a two-arm study comparing VRD-4187 (administered intravenously at a dose of 1.5 mg/kg on Days 1, 8, and 15 of each 28-day cycle) to investigator's choice of standard-of-care chemotherapy (topotecan or lurbinectedin). The trial enrolled 387 patients across 42 clinical sites in the United States and the European Union, with 194 patients randomized to the VRD-4187 treatment arm and 193 patients randomized to the control arm. The trial was conducted under IND Number 154832.
At the time the SPA was executed on June 10, 2024, the Marlowe Asset Management-2 trial was ongoing and enrollment was active. The SPA was negotiated and executed with knowledge on the part of both parties that interim data readouts from the trial were expected during the pre-closing period. The trial protocol included a pre-planned interim analysis to be conducted by an independent Data Monitoring Committee ("DMC") after approximately 75% of patients had completed at least one cycle of treatment. The parties' awareness of the pending interim analysis was reflected in the due diligence process, in Broadleaf's risk assessment, and in the negotiation of the MAE definition and closing conditions, as discussed further below.
C. The August 14, 2024 DMC Interim Analysis
On August 14, 2024, the independent Data Monitoring Committee convened to conduct its pre-planned interim analysis of the Marlowe Asset Management-2 trial. The DMC, composed of five independent clinicians and biostatisticians with expertise in oncology clinical trials, reviewed unblinded safety and efficacy data from the trial. Following its review, the DMC issued a formal recommendation to suspend enrollment in the Marlowe Asset Management-2 trial and to implement dose modification in the VRD-4187 treatment arm based on the observed safety data. The DMC's recommendation to suspend enrollment is an extraordinary measure, reserved for circumstances in which the committee concludes that the risk-benefit profile of the investigational agent is sufficiently unfavorable to warrant halting further patient exposure at the current dose.
Penterra received formal notice of the DMC findings from Veridian on August 16, 2024, two days after the DMC meeting, pursuant to Veridian's notification obligations under SPA § 5.1(b), which requires the Company to promptly notify Buyer of any event, development, or occurrence that would reasonably be expected to result in a failure of any condition set forth in Article VII of the SPA. The notification was delivered via email from Dr. Julian Marek (Veridian's CEO) to Thomas F. Holbrook (Penterra's General Counsel), with a copy to Rebecca Whitmore (Zalcourt Archer & Cole LLP). The notification included a summary of the DMC's findings and the text of the DMC's recommendation, but did not include the full unblinded dataset.
On August 19, 2024, Broadleaf Scientific Consulting LLC delivered a supplemental clinical assessment to Penterra, prepared by Dr. Raymond Kapoor and a team of oncology and biostatistics specialists, confirming the gravity of the safety signals observed in the Marlowe Asset Management-2 interim data. Broadleaf's supplemental assessment concluded that the safety profile of VRD-4187 at the 1.5 mg/kg dose "presents a fundamentally unacceptable risk-benefit profile that would be expected to be viewed as a serious obstacle to regulatory approval in any major jurisdiction" and that the efficacy data "does not support the conclusion that VRD-4187 offers a clinically meaningful benefit over existing therapies for relapsed/refractory SCLC."
The key interim data findings from the DMC analysis, as reported to Penterra and subsequently confirmed by Broadleaf, are as follows:
Grade ≥3 Cytokine Release Syndrome (CRS): The incidence of Grade 3 or higher CRS in the VRD-4187 treatment arm was 23.4% (approximately 45 of 194 patients), compared to 4.1% in the control arm (approximately 8 of 193 patients). This represents a difference of 19.3 percentage points and an approximately 5.7-fold higher rate of serious CRS in the VRD-4187 arm. CRS is a systemic inflammatory response that can be life-threatening when it occurs at Grade 3 or higher severity, often requiring intensive care unit admission, vasopressor support, and/or mechanical ventilation. The observed CRS rate in the VRD-4187 arm is substantially higher than what was anticipated based on the Phase I dose-escalation data, which reported a Grade ≥3 CRS rate of approximately 8–12% at the 1.5 mg/kg dose level in a smaller patient cohort. The escalation from the Phase I safety profile to the Phase II safety profile raises serious concerns about the reproducibility and manageability of VRD-4187's toxicity in a broader patient population.
Treatment-Related Deaths: Seven deaths attributable to the study treatment were recorded in the VRD-4187 arm (3.6% of 194 patients), compared to one death in the control arm (0.5% of 193 patients). This represents a seven-fold higher rate of treatment-related mortality in the VRD-4187 arm. The seven deaths in the treatment arm included five deaths attributed to severe CRS-related complications and two deaths attributed to immune-mediated neurotoxicity. The occurrence of seven treatment-related deaths in a Phase II trial of 194 patients is an exceptionally serious safety signal that raises fundamental questions about the drug's risk-benefit profile and the viability of continuing development at any dose without major protocol modifications.
Overall Response Rate (ORR): The overall response rate — the primary efficacy endpoint of the Marlowe Asset Management-2 trial — was 31.4% in the VRD-4187 treatment arm compared to 28.9% in the control arm, a difference of 2.5 percentage points. This difference was not statistically significant (p = 0.58), indicating that VRD-4187's efficacy is not materially better than the standard of care in the study population. The failure to demonstrate a statistically significant efficacy advantage is of critical importance: even if the safety profile were acceptable, the absence of a meaningful efficacy signal would undermine the case for regulatory approval, commercial viability, and clinical adoption of VRD-4187.
The combination of a severely unfavorable safety profile — characterized by a markedly elevated rate of life-threatening CRS and treatment-related mortality — and a lack of meaningful efficacy improvement presents a fundamentally adverse risk-benefit profile for VRD-4187 at the tested dose. In the assessment of Broadleaf Scientific Consulting, this combination of safety and efficacy data "would be viewed by FDA reviewers and by the broader oncology community as disqualifying for VRD-4187 at the 1.5 mg/kg dose level in the relapsed/refractory SCLC indication."
We note that on August 28, 2024, three days after the date of this memorandum, Veridian is expected to implement Protocol Amendment v4.0 to the Marlowe Asset Management-2 trial, which will add mandatory tocilizumab prophylaxis (a pre-treatment with an IL-6 receptor antagonist intended to mitigate the severity of CRS) and reduce the starting dose of VRD-4187 from 1.5 mg/kg to 0.75 mg/kg. We understand from informal communications that Penterra was not consulted prior to the decision to implement this protocol amendment, raising separate questions regarding compliance with SPA § 5.1 interim operating covenants, which require Veridian to operate its business in the ordinary course and to obtain Penterra's prior written consent before taking specified actions outside the ordinary course. The protocol amendment and its implications for the interim operating covenant analysis will be addressed in a separate memorandum.
III. CONTRACTUAL FRAMEWORK: MATERIAL ADVERSE EFFECT DEFINITION
A. SPA § 1.1 — Definition of "Material Adverse Effect"
Section 1.1 of the SPA defines "Material Adverse Effect" as follows:
"Material Adverse Effect" means any event, change, development, occurrence, condition, or effect that, individually or in the aggregate, has had or would reasonably be expected to have a material adverse effect on (a) the business, results of operations, financial condition, or assets of the Company, taken as a whole, or (b) the ability of the Sellers to consummate the Transactions contemplated by this Agreement.
This definition is a customary formulation that has been widely adopted in M&A transactions and has been the subject of extensive analysis by the Delaware courts. Several features of the definition warrant specific attention.
First, the definition employs both a backward-looking standard ("has had") and a forward-looking standard ("would reasonably be expected to have"). This dual temporal orientation is significant: it means that Penterra need not demonstrate that the Marlowe Asset Management-2 data has already caused quantifiable financial harm to Veridian in order to establish an MAE. Rather, it is sufficient to demonstrate that the data "would reasonably be expected to have" a material adverse effect on Veridian's business, results of operations, financial condition, or assets going forward. For a pre-commercial, clinical-stage biotechnology company with no product revenue, this forward-looking prong is particularly important, as the impact of adverse clinical data may not manifest immediately in financial statements but will nevertheless substantially impair the company's future prospects and enterprise value.
Second, the definition requires assessment of the impact "on the Company, taken as a whole." This qualifier is a standard feature of MAE definitions and is intended to prevent a buyer from invoking an MAE based on an adverse development affecting only a minor, peripheral aspect of the target's business. However, in the case of Veridian — a single-product-focus company whose entire enterprise value is derived overwhelmingly from VRD-4187 — the "taken as a whole" qualifier actually reinforces Penterra's position. Because VRD-4187 constitutes substantially all of Veridian's value, harm to VRD-4187 is effectively harm to the company as a whole. There is no meaningful distinction between the fortunes of VRD-4187 and the fortunes of Veridian as an enterprise.
Third, the definition encompasses effects on the "business, results of operations, financial condition, or assets" of the Company. These are four distinct categories, and an adverse effect on any one of them — not all four — is sufficient to establish an MAE. As discussed in Part V below, the Marlowe Asset Management-2 data adversely affects each of these categories.
B. Enumerated Carveouts
The MAE definition in SPA § 1.1 provides that, notwithstanding the foregoing, the term "Material Adverse Effect" shall not include any event, change, development, occurrence, condition, or effect arising from or relating to:
(i) changes in general economic or political conditions in the United States or any other jurisdiction in which the Company conducts business;
(ii) changes in conditions generally affecting the biotechnology or pharmaceutical industries in which the Company operates;
(iii) changes in applicable law, regulation, or the interpretation thereof, or changes in accounting principles generally accepted in the United States (GAAP);
(iv) pandemics, epidemics, or disease outbreaks, including COVID-19 and any similar public health emergencies declared by the World Health Organization or any national governmental authority;
(v) natural disasters, earthquakes, hurricanes, floods, acts of war, armed hostilities, sabotage, or terrorism, or any escalation or worsening of any of the foregoing;
(vi) changes in the financial, banking, or securities markets generally, including changes in interest rates or exchange rates; and
(vii) the announcement or pendency of the Transactions contemplated by this Agreement, including the impact thereof on the relationships of the Company with its employees, customers, suppliers, regulators, or other third parties.
These carveouts serve to allocate between the parties the risk of specific categories of adverse developments that are exogenous to the target's business or that are attributable to the transaction itself. The carveouts are an essential component of the MAE definition and must be analyzed carefully to determine whether any of them might shield Veridian from an MAE finding.
Analysis of Carveout Applicability to the Marlowe Asset Management-2 Data:
Carveout (i) — General Economic or Political Conditions: This carveout is plainly inapplicable. The Marlowe Asset Management-2 interim clinical data is a company-specific event arising from Veridian's own clinical trial of its own drug candidate. The data has no connection to general economic conditions, political developments, GDP growth, inflation, unemployment, or any other macroeconomic factor.
Carveout (ii) — Conditions Affecting the Biotechnology or Pharmaceutical Industries Generally: This carveout warrants closer analysis and is the one most likely to be invoked by Veridian. We anticipate that Veridian will argue that clinical trial failures are an inherent risk of the biotechnology industry and that adverse Phase II data is a "condition" affecting the industry generally. We address this argument in detail in Part VI.C below and conclude that it should not apply. The carveout is designed to exclude macroeconomic or sector-wide conditions — such as a general decline in biotech company valuations, a sector-wide increase in FDA regulatory scrutiny, or a systemic reduction in venture capital funding for biotech companies — that affect all or most participants in the industry. A company-specific clinical trial failure for a specific drug candidate is not an "industry condition" within the meaning of this carveout. If this carveout were interpreted to exclude all clinical trial failures from the scope of the MAE definition, it would effectively render the MAE clause meaningless for any acquisition of a clinical-stage biotechnology company — a result that cannot have been intended by the parties.
Carveout (iii) — Changes in Law or GAAP: This carveout is inapplicable. The Marlowe Asset Management-2 data does not arise from or relate to any change in law, regulation, or accounting standards.
Carveout (iv) — Pandemics: This carveout is inapplicable. While the COVID-19 pandemic and its aftermath have affected clinical trial operations in prior years, there is no indication that the Marlowe Asset Management-2 safety or efficacy data is in any way attributable to pandemic-related factors.
Carveout (v) — Natural Disasters, War, and Terrorism: This carveout is inapplicable. The clinical trial data is unrelated to any natural disaster, military conflict, or act of terrorism.
Carveout (vi) — Financial Markets: This carveout is inapplicable. The clinical data has no connection to changes in financial, banking, or securities markets, interest rates, or exchange rates.
Carveout (vii) — Announcement or Pendency of the Transactions: This carveout is inapplicable. The Marlowe Asset Management-2 data is the product of an ongoing clinical trial and is entirely independent of the announcement or pendency of the Penterra-Veridian transaction. There is no basis to argue that the clinical safety data was caused by or related to the transaction itself.
In summary, none of the enumerated carveouts clearly applies to the Marlowe Asset Management-2 interim data. The only carveout that Veridian is reasonably likely to invoke — carveout (ii) for industry conditions — is, in our view, inapplicable to company-specific clinical trial results, as discussed further below. A more detailed carveout analysis, including a comprehensive assessment of each carveout and supporting case law, will be provided in a separate memorandum.
C. Disproportionate Impact Exception
Carveouts (i) through (vi) are each subject to a disproportionate impact exception. Specifically, the SPA provides:
provided, however, that any event, change, development, occurrence, condition, or effect referred to in clauses (i) through (vi) above shall be taken into account in determining whether a Material Adverse Effect has occurred or would reasonably be expected to occur to the extent that such event, change, development, occurrence, condition, or effect has a disproportionate effect on the Company relative to other companies of similar size operating in the biotechnology industry.
This "disproportionate impact" exception is a standard carve-back provision that preserves the buyer's ability to invoke the MAE clause even if a carveout would otherwise apply, provided the buyer can demonstrate that the relevant event has a disproportionately greater impact on the target company relative to its industry peers.
Even if Veridian were to argue that carveout (ii) (industry conditions) applies to the Marlowe Asset Management-2 data — a position we believe is incorrect for the reasons discussed above — Penterra would have a strong argument under the disproportionate impact exception. VRD-4187 is Veridian's lead and most advanced clinical candidate, representing the overwhelming majority of the Company's enterprise value. A clinical trial failure of this magnitude — with seven treatment-related deaths and a 23.4% rate of Grade ≥3 CRS — disproportionately impacts Veridian relative to other clinical-stage biotechnology companies, which typically have diversified pipelines or earlier-stage programs that are not subject to the same concentration risk. Veridian's near-total dependence on VRD-4187 makes it uniquely vulnerable to adverse clinical data for that specific candidate.
A separate detailed analysis of the disproportionate impact exception, including a comparison to other similarly situated biotechnology companies, will be provided in a forthcoming memorandum.
D. Relevant Closing Conditions
The SPA conditions Penterra's obligation to close the Transactions on the satisfaction (or waiver by Buyer) of certain conditions precedent set forth in Article VII of the SPA. Two conditions are directly relevant to the MAE analysis:
SPA § 7.2(a) — Accuracy of Representations and Warranties: The representations and warranties of the Sellers set forth in Article III of the SPA must be true and correct in all respects as of the date of the SPA and as of the Closing Date as though made on and as of the Closing Date (except for representations and warranties that speak as of a specified date, which must be true and correct as of such date). Representations and warranties that are qualified by "materiality" or "Material Adverse Effect" qualifiers must be true and correct in all respects, and representations and warranties that are not so qualified must be true and correct in all material respects. If the Marlowe Asset Management-2 data constitutes an MAE, certain of Veridian's representations — including, for example, representations regarding the absence of any Material Adverse Effect since a specified date, representations regarding compliance with applicable laws and regulations, and representations regarding the clinical status of the Company's drug candidates — may no longer be true and correct, giving rise to a failure of this closing condition.
SPA § 7.2(b) — Absence of Material Adverse Effect: Since the date of the SPA, there shall not have occurred any Material Adverse Effect. This is a standalone closing condition that operates independently of the representation and warranty bring-down in § 7.2(a). If the Marlowe Asset Management-2 data constitutes a Material Adverse Effect, this closing condition has not been satisfied, and Penterra would not be obligated to close the Transactions (absent a waiver by Buyer).
Both conditions set forth in §§ 7.2(a) and 7.2(b) must be satisfied (or waived by Buyer) as a prerequisite to Penterra's obligation to close. The failure of either condition independently excuses Penterra's obligation to proceed.
SPA § 8.1(d) — Buyer's Termination Right: The SPA grants the Buyer the right to terminate the agreement if the conditions to Buyer's obligation to close set forth in Section 7.2 are not satisfied and are not reasonably capable of being satisfied prior to the Outside Date of December 10, 2024, provided that the Buyer is not then in material breach of any of its representations, warranties, covenants, or agreements under the SPA. This provision establishes the mechanism by which Penterra may elect to terminate the transaction if the MAE closing condition is not satisfied and cannot reasonably be cured prior to the contractual deadline for closing.
IV. DELAWARE LAW FRAMEWORK FOR MAE DETERMINATIONS
A. General Principles
The interpretation and enforcement of Material Adverse Effect clauses in acquisition agreements is governed by well-developed principles of Delaware law, which controls the SPA pursuant to the governing law provision in SPA § 10.5. Under Delaware law, the buyer bears the burden of proving that a Material Adverse Effect has occurred. This allocation of the burden of proof reflects the Delaware courts' recognition that MAE clauses allocate between the parties the risk of adverse developments occurring between signing and closing, and that a buyer's invocation of an MAE clause to terminate a transaction is an extraordinary remedy with significant consequences for the target company and its stockholders.
Delaware courts have historically applied a demanding standard for MAE determinations, reflecting a policy preference for the enforcement of merger and acquisition agreements and a skepticism of buyer's remorse. The courts have recognized that acquirors agree to MAE closing conditions as a protection against genuinely material, unexpected deteriorations in the target's business — not as an escape hatch to be invoked whenever the buyer experiences post-signing anxiety about the transaction or when adverse developments fall within the range of reasonably foreseeable business risks.
The seminal case in Delaware MAE jurisprudence is the Court of Chancery's decision in Akorn, Inc. v. Fresenius Kabi AG, C.A. No. 2018-0300-JTL (Del. Ch. Oct. 1, 2018), aff'd, 198 A.3d 724 (Del. 2018). Akorn was the first — and, to our knowledge, remains the only — Delaware case in which a court found that a Material Adverse Effect had occurred in a contested proceeding and validated a buyer's termination of a merger agreement on MAE grounds. The decision was affirmed by the Delaware Supreme Court in a one-paragraph order adopting the Court of Chancery's analysis. Akorn established the analytical framework that Delaware courts apply to MAE claims and provides the most authoritative guidance on the factual circumstances that can support an MAE finding.
The Court of Chancery in Akorn articulated that a Material Adverse Effect must be "material when viewed from the long-term perspective of a reasonable acquiror." This formulation incorporates several important elements: the materiality standard requires a showing of genuinely significant adverse impact (not a minor or transient setback); the "long-term perspective" element introduces a durational component (discussed below); and the "reasonable acquiror" standard incorporates an objective, reasonable-person analysis rather than a subjective inquiry into the particular buyer's expectations or motivations.
B. The Durational Significance Standard
A central element of Delaware's MAE framework is the requirement of "durational significance." Delaware courts require that the adverse effect be durationally significant — meaning that it must persist over a commercially reasonable period, typically measured in years rather than weeks or months. The durational significance requirement distinguishes genuinely material adverse effects from temporary downturns, cyclical fluctuations, or short-term setbacks that, while potentially significant in the near term, do not fundamentally impair the target's long-term value or earnings potential.
In Akorn, the Court of Chancery found the durational significance standard satisfied where the target experienced severe regulatory and data integrity issues that threatened its core business — specifically, widespread failures in data integrity at the target's manufacturing facilities that imperiled its ability to obtain and maintain FDA approvals for its pharmaceutical products. The court emphasized that these issues were not temporary or easily remediated but rather represented systemic problems that would persist for years and require extensive corrective action.
Application to Veridian: The Marlowe Asset Management-2 data is not a temporary setback. A Phase II safety failure of the magnitude observed — 23.4% Grade ≥3 CRS, seven treatment-related deaths, and no statistically significant efficacy benefit — fundamentally undermines the commercial viability of VRD-4187 at the tested dose of 1.5 mg/kg. The data cannot be undone or explained away; it is part of the permanent clinical record for VRD-4187 and will be reviewed by the FDA in any future regulatory submission.
Even if Veridian proceeds with Protocol Amendment v4.0 (reducing the dose to 0.75 mg/kg and adding tocilizumab prophylaxis), the need for a materially different dosing regimen effectively resets the clinical development program. A dose reduction of this magnitude is not a minor protocol modification — it is a fundamental change to the therapeutic approach that would require, at a minimum: (i) new safety data demonstrating an acceptable toxicity profile at the reduced dose; (ii) new efficacy data demonstrating a clinically meaningful benefit at the reduced dose, which is far from assured given that dose reductions typically reduce both toxicity and efficacy; (iii) potentially a new Phase II trial or an expanded cohort study at the new dose level; and (iv) subsequent Phase III development if the Phase II data at the new dose is supportive. This process would take multiple years — conservatively, three to five years or more — and would require hundreds of millions of dollars in additional clinical development costs.
The FDA's partial clinical hold imposed on August 22, 2024, further confirms the durational nature of this setback. While the clinical hold will be analyzed in detail in a supplemental memorandum, it represents an independent regulatory action that imposes additional delays, compliance requirements, and uncertainty on the VRD-4187 development program.
VRD-4187's safety profile at the original dose of 1.5 mg/kg is unlikely to be rehabilitated. The drug's risk-benefit calculus has fundamentally and durably shifted. The clinical record now includes seven treatment-related deaths and a 23.4% rate of serious CRS, data that will be front and center in any future FDA review of VRD-4187, regardless of subsequent protocol modifications. As a clinical-stage company with no revenue, Veridian's entire enterprise value is derived from the probability-adjusted net present value of its pipeline, which is overwhelmingly concentrated in VRD-4187. The destruction of VRD-4187's near-term commercial prospects is plainly durationally significant to Veridian's business when measured from the long-term perspective of a reasonable acquiror.
C. Quantitative Materiality
While Delaware courts have not established a bright-line quantitative threshold for what constitutes a "material" adverse effect, the Akorn decision provides useful guidance. The Court of Chancery observed that a decline of approximately 20–25% in the target's EBITDA, measured against the acquiror's financial model, could suggest materiality, while noting that the analysis is not limited to any single financial metric. In Akorn, the target experienced EBITDA declines of approximately 50–86% across successive quarters, which the court found to far exceed the materiality threshold.
For a pre-revenue, clinical-stage company like Veridian, traditional financial metrics such as revenue, EBITDA, or net income are inapplicable. Veridian has $0 in revenue and negative EBITDA; it is not a company whose value can be measured by reference to current earnings. The relevant measure of materiality for a company like Veridian is the probability-adjusted value of its pipeline — specifically, the risk-adjusted net present value ("rNPV") of its clinical candidates, which is the standard valuation methodology employed by pharmaceutical acquirors and financial advisors in pricing clinical-stage biotech acquisitions.
Prior to the Marlowe Asset Management-2 data readout, VRD-4187 was valued by Penterra's internal financial models, by Garrison Zanthor & Co.'s fairness analysis, and by Broadleaf Scientific Consulting's clinical assessment as the principal source of the $900 million purchase price. The precise allocation of value between VRD-4187 and Veridian's other pipeline assets (VRD-5520 and VRD-6003) and platform technology (VeriTCE) was reflected in the models underlying the fairness opinion, but it is our understanding that VRD-4187 was attributed the substantial majority — likely in excess of 75–80% — of the aggregate transaction value.
Broadleaf Scientific Consulting's supplemental clinical assessment, delivered on August 19, 2024, concluded that the Marlowe Asset Management-2 data substantially reduces the probability of regulatory approval for VRD-4187. Broadleaf estimated that VRD-4187's probability of approval has declined from an estimated 35–40% pre-data readout to less than 10% in the absence of a major redesign of the clinical development program. This represents a reduction in probability-of-approval of approximately 25–30 percentage points, or a decline of approximately 65–75% from the pre-data estimate.
The impact of this probability-of-approval reduction on VRD-4187's risk-adjusted enterprise value is dramatic. Using standard rNPV methodology, a reduction in probability of approval from 37.5% (the midpoint of the 35–40% range) to 10% represents a reduction of approximately 73% in the probability-weighted value of VRD-4187. When applied to the portion of the $900 million purchase price attributable to VRD-4187 (conservatively estimated at 75–80% of the total, or approximately $675–720 million), the implied reduction in value is on the order of $490–530 million. This far exceeds any 20–25% materiality threshold that might be applied.
Even accounting for the residual value of Veridian's other pipeline candidates (VRD-5520 and VRD-6003), the VeriTCE platform technology, and the Company's cash and working capital, the aggregate destruction of value is staggering and plainly material by any reasonable measure.
D. Qualitative Factors
Beyond the quantitative analysis, Delaware courts consider qualitative factors in assessing whether a Material Adverse Effect has occurred. Several qualitative factors weigh heavily in favor of an MAE finding here.
Nature of the Adverse Development. A clinical trial safety failure is among the most consequential events that can befall a pharmaceutical or biotechnology company. Unlike revenue fluctuations, market conditions, or operational challenges — which may be temporary and may be addressed through management actions — a severe clinical safety failure directly implicates the company's core business of developing and commercializing therapeutics. The safety data from Marlowe Asset Management-2 goes to the heart of VRD-4187's viability as a drug candidate and, by extension, to the heart of Veridian's business.
Treatment-Related Deaths. The occurrence of seven treatment-related deaths in the VRD-4187 arm of a Phase II trial of 194 patients is an extraordinarily serious safety signal. Each of these deaths represents a patient who died as a consequence of receiving the investigational treatment. Treatment-related deaths in clinical trials are among the most significant adverse events from both a regulatory and a liability perspective. They create substantial obstacles to future regulatory approval (as the FDA will require extensive justification and risk mitigation before permitting further development), they expose the Company to potential product liability claims, and they generate significant negative attention within the medical and regulatory communities that can persist for years.
Non-Significant Efficacy Differential. The overall response rate data (31.4% versus 28.9%, p = 0.58) demonstrates that VRD-4187, at the tested dose, does not offer a statistically significant — or even a clinically meaningful — efficacy benefit over the standard of care. This is particularly damaging because it means that VRD-4187 exposes patients to substantially elevated safety risks without providing a compensating therapeutic benefit. A drug that is both more dangerous and no more effective than existing treatments has an untenable risk-benefit profile. The p-value of 0.58 is far from the conventional threshold for statistical significance (p < 0.05), indicating that the observed efficacy difference is indistinguishable from random chance.
DMC Recommendation to Suspend Enrollment. The DMC's recommendation to suspend enrollment is an independent, objective validation of the severity of the safety signal by a panel of expert clinicians and biostatisticians who reviewed the unblinded data. DMC recommendations to suspend enrollment are rare and are reserved for circumstances in which the committee concludes that continuing the trial at the current dose and design would expose patients to unacceptable risk. The DMC's recommendation carries significant weight as an independent, expert assessment that the Marlowe Asset Management-2 data reflects a genuine and serious safety problem, not a statistical anomaly.
Competitive Landscape. The SCLC therapeutic landscape is highly competitive, with multiple pharmaceutical companies pursuing DLL3-targeting agents and other novel immunotherapeutic approaches. VRD-4187's safety failure not only impairs Veridian's competitive position but also increases the likelihood that competing agents with more favorable safety profiles will capture the SCLC treatment paradigm. The window of commercial opportunity for VRD-4187 is narrowing, and the multi-year delay required to redesign the clinical program may cause Veridian to fall irretrievably behind competitors.
V. APPLICATION TO THE SPA: PRONG-BY-PRONG ANALYSIS
A. Prong (a): Material Adverse Effect on the Business, Results of Operations, Financial Condition, or Assets of the Company
The MAE definition in SPA § 1.1 encompasses adverse effects on four distinct categories: (1) the business, (2) the results of operations, (3) the financial condition, and (4) the assets of the Company, taken as a whole. An adverse effect on any one of these categories is sufficient to establish an MAE. We analyze each category below.
1. Impact on Business
Veridian's core business is the discovery, development, and (ultimately) commercialization of immuno-oncology therapeutics leveraging its proprietary VeriTCE platform. VRD-4187 is the Company's lead clinical candidate, its most advanced pipeline asset, and the focus of the vast majority of the Company's research and development efforts and resources. The Marlowe Asset Management-2 trial was the centerpiece of Veridian's clinical development strategy and the critical path to potential regulatory approval and commercialization of VRD-4187.
The Marlowe Asset Management-2 interim data calls into question VRD-4187's viability as a therapeutic candidate at the tested dose of 1.5 mg/kg. The combination of an unacceptably elevated safety profile (23.4% Grade ≥3 CRS, 3.6% treatment-related mortality) and no statistically significant efficacy benefit (ORR 31.4% versus 28.9%, p = 0.58) means that VRD-4187 cannot be advanced toward regulatory approval at the current dose and trial design. The drug, as tested, poses an untenable risk-benefit profile that would not meet the FDA's standards for approval.
Veridian's implementation of Protocol Amendment v4.0 — reducing the dose from 1.5 mg/kg to 0.75 mg/kg and adding mandatory tocilizumab prophylaxis — is an acknowledgment that the current development program has failed at the tested dose. However, the protocol amendment does not remediate the damage to VRD-4187's development trajectory. The reduced dose of 0.75 mg/kg is untested for efficacy in a randomized setting, and there is no assurance that the lower dose will be efficacious. In the field of bispecific T-cell engagers and related immunotherapeutic agents, dose-response relationships are well-established, and dose reductions typically result in reductions in both toxicity and efficacy. If VRD-4187 at 0.75 mg/kg does not produce a meaningful efficacy signal, the clinical program will have effectively failed, and the candidate will need to be either abandoned or subjected to further dose-finding studies that could take years.
Moreover, the protocol amendment effectively resets the clinical development timeline. What was previously an ongoing Phase II trial with the potential for a data readout supporting a Phase III trial and, eventually, an NDA submission is now a substantially modified study that will require new dose-escalation cohorts, new safety monitoring periods, and potentially a new randomized efficacy assessment. The transition from the current Phase II to a pivotal Phase III trial — which was a key milestone in Penterra's valuation model — has been delayed by years, if not indefinitely.
The financial implications of this reset are profound. Veridian, as a pre-commercial company with no revenue, reported cash and cash equivalents of approximately $112.4 million as of March 31, 2024, and a net loss of approximately $87.3 million for fiscal year 2023. At this historical burn rate, Veridian's cash runway extends approximately 15–16 months — insufficient to fund the multi-year, redesigned clinical development program that VRD-4187 now requires. Veridian would need to raise hundreds of millions of dollars in additional financing to sustain the development program, and such financing would likely be available only at terms reflecting the substantially diminished value of the pipeline in light of the Marlowe Asset Management-2 data. The Company faces a realistic risk of being unable to fund continued development of VRD-4187, a risk that further underscores the material adverse impact on its business.
2. Impact on Results of Operations
Veridian has no product revenue (FY2023 revenue: $0). For a clinical-stage biotechnology company that is entirely pre-commercial, "results of operations" are best understood by reference to research and development progress, pipeline advancement milestones, clinical trial outcomes, and the efficiency with which the Company converts its capital into clinical data supporting future regulatory approval and commercialization.
By this measure, the Marlowe Asset Management-2 data represents a catastrophic deterioration in Veridian's results of operations. The DMC's recommendation to suspend enrollment has halted forward progress on Veridian's most valuable clinical program. The subsequent FDA partial clinical hold (to be analyzed separately) has imposed additional regulatory constraints. The Company's most significant research and development program is now effectively paused, with no clear timeline for resumption of enrollment at a modified dose.
Meanwhile, Veridian's operating losses will continue unabated. The Company will continue to incur general and administrative expenses, research and development expenditures (including costs associated with the ongoing management of enrolled patients, the implementation of Protocol Amendment v4.0, and the preparation of safety reports for the FDA), and other operational costs — all without the prospect of generating clinical data that advances VRD-4187 toward approval on the timeline contemplated at the time of signing. The net result is that Veridian is burning cash at a rate of approximately $87 million per year with no offsetting progress toward its core business objective.
3. Impact on Financial Condition
Veridian's financial condition is inextricably linked to the value of its pipeline and its ability to attract additional capital. As a pre-revenue company, Veridian's financial condition is measured not by income statement metrics but by its balance sheet strength (cash position), its ability to raise additional financing, and the probability-adjusted value of its pipeline assets.
The Marlowe Asset Management-2 data has severely impaired each of these financial condition indicators. The probability-adjusted value of VRD-4187 has declined dramatically, as discussed in Part IV.C above, with Broadleaf estimating a reduction in probability of approval from 35–40% to less than 10%. This reduction in the value of Veridian's principal asset directly impairs the Company's financial condition as measured by any reasonable valuation methodology.
Veridian's ability to raise additional equity or debt financing at favorable terms has been severely compromised. Prior to the Marlowe Asset Management-2 data, Veridian could have reasonably expected to attract Series E or later-stage financing at a valuation reflecting VRD-4187's Phase II progress and the pending Penterra acquisition. In the wake of the adverse clinical data and the FDA clinical hold, any future fundraising will occur at a substantially reduced valuation, with more onerous terms and potentially punitive liquidation preferences that would further dilute existing stockholders. There is also a realistic possibility that Veridian may be unable to attract sufficient financing to continue operations, particularly given the competitive dynamics of the SCLC therapeutic landscape and the broader financing environment for clinical-stage biotechnology companies with impaired lead candidates.
Veridian's current cash position of approximately $112.4 million (as of March 31, 2024) provides limited runway. At the Company's historical burn rate of approximately $87 million per year, this cash reserve is sufficient for approximately 15–16 months of operations — a period that is plainly insufficient to fund the multi-year, redesigned clinical development program required for VRD-4187. The inadequacy of Veridian's cash position relative to its clinical development needs represents a material impairment of the Company's financial condition.
4. Impact on Assets
Veridian's principal assets are: (a) its intellectual property portfolio, including the VeriTCE platform technology and the patent portfolio covering VRD-4187 and related compositions of matter, methods of use, and manufacturing processes; (b) its IND (No. 154832) for VRD-4187; (c) the clinical data generated in the Marlowe Asset Management-1 (Phase I) and Marlowe Asset Management-2 (Phase II) trials; (d) its workforce, including the scientific and clinical development teams; and (e) its cash and cash equivalents.
The Marlowe Asset Management-2 data does not destroy Veridian's intellectual property per se — the VeriTCE platform patents remain valid and the VRD-4187 composition of matter patents remain enforceable. However, the practical economic value of these intellectual property assets is inseparable from the clinical data that supports (or, in this case, undermines) the commercial viability of the drug candidates they protect. A patent covering a drug candidate that cannot obtain regulatory approval due to an unacceptable safety profile has dramatically less economic value than a patent covering a drug candidate with a favorable risk-benefit profile and a clear regulatory pathway. The Marlowe Asset Management-2 data has materially diminished the economic value of Veridian's intellectual property assets by undermining the commercial prospects of VRD-4187, the most valuable asset in the portfolio.
The IND for VRD-4187 (No. 154832), which is now subject to an FDA partial clinical hold, has been directly impaired as a regulatory asset. The clinical hold restricts Veridian's ability to conduct clinical investigations under the IND and imposes additional requirements for resumption of clinical activities. This impairment is both legally significant (as it restricts the Company's ability to develop its lead asset) and economically significant (as it delays the regulatory pathway and increases the cost and uncertainty of development).
B. Prong (b): Ability of the Sellers to Consummate the Transactions
The second prong of the MAE definition concerns the ability of the Sellers to consummate the Transactions contemplated by the SPA. This prong is directed at legal or practical impediments to the Sellers' ability to transfer the shares and complete the sale — for example, the inability to obtain required consents, the imposition of legal restraints, or the occurrence of events that prevent the mechanical completion of the transaction.
The Marlowe Asset Management-2 data does not directly impair the Sellers' legal ability to transfer 100% of the outstanding capital stock of Veridian to Penterra. There is no legal or regulatory impediment to the stock transfer arising from the clinical data per se. Accordingly, our analysis focuses primarily on Prong (a), which we believe provides a substantially stronger basis for an MAE determination.
VI. VERIDIAN'S ANTICIPATED COUNTERARGUMENTS
In the event that Penterra seeks to invoke the MAE clause and terminate the SPA, Veridian and the Stockholder Representative are likely to raise several counterarguments. We address each anticipated counterargument below, together with our assessment of Penterra's responsive arguments.
A. "The Data Is Preliminary / Interim"
Veridian will likely argue that the DMC interim analysis is preliminary and incomplete, that additional data maturation may alter the safety and efficacy profile of VRD-4187, and that interim analyses are inherently "noisy" and subject to statistical fluctuation. Veridian may contend that it is premature to draw definitive conclusions from an interim data readout and that the full dataset — once all enrolled patients have completed the study — may paint a more favorable picture.
Penterra's Response: While it is true that interim data is by nature incomplete, the safety signal observed in the Marlowe Asset Management-2 interim analysis is stark, severe, and statistically significant. A 19.3-percentage-point difference in Grade ≥3 CRS incidence (23.4% versus 4.1%) is not within the range of statistical noise or random fluctuation; it is a robust and highly significant safety difference that is extremely unlikely to be reversed or materially attenuated by additional data. The seven treatment-related deaths in the VRD-4187 arm (versus one in the control arm) — a seven-fold differential — represent concrete, irreversible adverse events that cannot be explained away by appeals to statistical variability.
Critically, the DMC itself — an independent body with access to the full unblinded dataset and with extensive expertise in oncology clinical trial safety monitoring — concluded that the safety data warranted suspension of enrollment, an extraordinary recommendation that is made only when the committee determines that continuing the trial at the current dose would expose patients to unacceptable risk. The DMC's independent judgment lends objective validation to the severity and reliability of the safety signal and substantially undermines any argument that the interim data is too preliminary to support conclusions.
Moreover, the MAE definition in the SPA covers events that "would reasonably be expected to have" a material adverse effect, expressly encompassing prospective analysis. Penterra need not wait for the final data readout to invoke the MAE clause; it is sufficient that the interim data creates a reasonable expectation of material adverse consequences for Veridian's business — and the record overwhelmingly supports that conclusion.
B. "The Protocol Amendment (v4.0) Addresses the Safety Concerns"
Veridian will point